NeuroOne Medical Technologies Shares Rise 4.9% After 510(k) Submission
By Chris Wack
NeuroOne Medical Technologies shares were up 4.9% to $1.29 after the company said it submitted a 510(k) application to the U.S. Food and Drug Administration for its OneRF Ablation System.
The stock is up 21% in the past 12 months.
The company said the OneRF technology uses already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency generator.
If cleared by the FDA, NeuroOne's OneRF 510(k) submission represents the first step in bringing the system to market.
NeuroOne said it expects to see initial feedback from the FDA no later than Aug. 7.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 12, 2023 13:06 ET (17:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth